You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 9,023,790


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,023,790
Title:Posaconazole intravenous solution formulations stabilized by substituted .beta.-cyclodextrin
Abstract: The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified .beta.-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties.
Inventor(s): Heimbecher; Susan K. (Morris Plains, NJ), Monteith; David (Pittstown, NJ), Pipkin; James D. (Lawrence, KS)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:13/704,145
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,023,790
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use; Device;
Patent landscape, scope, and claims:

United States Patent 9,023,790: A Detailed Analysis of Scope and Claims

Introduction

United States Patent 9,023,790, titled "Pharmaceutical Compositions of Posaconazole," is a significant patent in the pharmaceutical industry, particularly in the field of antifungal treatments. This patent, assigned to Merck Sharp & Dohme Corp., covers specific formulations of posaconazole, a triazole antifungal drug. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background on Posaconazole

Posaconazole is an antifungal medication used to treat invasive infections caused by Candida and Aspergillus species, especially in patients with weakened immune systems[4].

Patent Overview

Patent Number and Date

The patent number is 9,023,790, and it was granted on May 5, 2015[5].

Assignee

The patent is assigned to Merck Sharp & Dohme Corp., a major pharmaceutical company.

Scope of the Patent

Invention Description

The patent describes pharmaceutical compositions of posaconazole, specifically formulations that enhance the bioavailability and stability of the drug. The invention focuses on improving the pharmacokinetic properties of posaconazole, which is crucial for its effectiveness in treating fungal infections[5].

Key Features

  • Formulation: The patent details various formulations, including suspensions and tablets, designed to optimize the absorption of posaconazole.
  • Pharmacokinetic Properties: Clinical trials have shown that these formulations achieve acceptable pharmacokinetic properties, such as improved bioavailability and stability[5].

Claims Analysis

Independent Claims

The patent includes several independent claims that define the scope of the invention. These claims typically describe the composition, method of preparation, and use of the posaconazole formulations.

Dependent Claims

Dependent claims further specify the details of the independent claims, such as the exact composition ratios, preparation methods, and specific uses of the formulations.

Claim Length and Count

Research on patent claims suggests that the length and count of claims can be indicative of patent scope. Narrower claims with fewer dependencies often indicate a more focused and potentially stronger patent[3].

Patent Landscape

Related Patents

The patent landscape for posaconazole includes several other patents related to its formulation, use, and manufacturing processes. For example, patents like US5703079 and US5661151 also cover various aspects of posaconazole formulations and their uses[4].

Global Patent Family

Using tools like the Global Dossier provided by the USPTO, one can see the patent family for this specific application, including related applications filed at participating IP Offices. This helps in understanding the global protection and status of the patent[1].

Citation Data

The Common Citation Document (CCD) application can provide insights into the prior art cited by various patent offices for the same invention, helping to assess the novelty and non-obviousness of the patent claims[1].

Economic and Legal Implications

Patent Scope and Quality

The scope of a patent, as measured by metrics like independent claim length and count, can impact its quality and the incentives for innovation. Narrower claims, as seen in this patent, are often associated with a higher probability of grant and shorter examination processes[3].

Licensing and Litigation

The clarity and breadth of patent claims can influence licensing and litigation costs. Well-defined claims, such as those in this patent, can reduce the likelihood of disputes and enhance the value of the patent[3].

Search and Analysis Tools

USPTO Resources

Tools like the Patent Public Search, Global Dossier, and the Patent Examination Data System (PEDS) provided by the USPTO are essential for conducting thorough searches and analyses of patents like US 9,023,790[1].

International Databases

Searching international patent databases, such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO), can help in understanding the global patent landscape for posaconazole formulations[1].

Conclusion

United States Patent 9,023,790 is a significant contribution to the field of antifungal treatments, particularly in the formulation and delivery of posaconazole. Understanding the scope, claims, and broader patent landscape is crucial for both legal and business strategies.

Key Takeaways

  • Patent Scope: The patent focuses on improving the pharmacokinetic properties of posaconazole through specific formulations.
  • Claims Analysis: The patent includes independent and dependent claims that define the composition, preparation, and use of the formulations.
  • Patent Landscape: The patent is part of a larger family of patents related to posaconazole, with global protection and citation data available through various tools.
  • Economic Implications: The clarity and breadth of the claims can impact licensing, litigation, and the overall value of the patent.
  • Search Tools: Utilizing USPTO and international patent databases is essential for thorough analysis.

FAQs

What is the main focus of United States Patent 9,023,790?

The main focus of this patent is on pharmaceutical compositions of posaconazole that enhance its bioavailability and stability.

Who is the assignee of this patent?

The patent is assigned to Merck Sharp & Dohme Corp.

How can one access the global patent family for this patent?

Using the Global Dossier service provided by the USPTO, users can access the file histories of related applications from participating IP Offices.

What metrics can be used to measure the scope of a patent?

Metrics such as independent claim length and count can be used to measure the scope of a patent and assess its quality[3].

Where can one find detailed information on the claims of this patent?

Detailed information on the claims can be found in the patent document itself, available through the USPTO's Patent Public Search tool or other patent databases[1].

Sources

  1. USPTO: Search for patents - USPTO. (2018, October 18).
  2. USPTO: Patent Claims Research Dataset - USPTO. (2017, August 28).
  3. SSRN: Patent Claims and Patent Scope. (2016, September 29).
  4. DrugBank: Posaconazole: Uses, Interactions, Mechanism of Action - DrugBank.
  5. Google APIs: United States Patent - googleapis.com. (2011, June 24).

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,023,790

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merck Sharp Dohme NOXAFIL posaconazole SOLUTION;INTRAVENOUS 205596-001 Mar 13, 2014 AP RX Yes Yes 9,023,790 ⤷  Subscribe Y TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER ⤷  Subscribe
Merck Sharp Dohme NOXAFIL posaconazole SOLUTION;INTRAVENOUS 205596-001 Mar 13, 2014 AP RX Yes Yes 9,023,790 ⤷  Subscribe Y PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS ⤷  Subscribe
Merck Sharp Dohme NOXAFIL posaconazole SOLUTION;INTRAVENOUS 205596-001 Mar 13, 2014 AP RX Yes Yes 9,023,790 ⤷  Subscribe Y PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WHO ARE SEVERELY IMMUNOCOMPROMISED ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,023,790

PCT Information
PCT FiledJune 24, 2011PCT Application Number:PCT/US2011/041715
PCT Publication Date:January 12, 2012PCT Publication Number: WO2012/005973

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.